Khalifa, M.A., et al. Yemeni J Med Sci. 2025; 19: 70 - 83
https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

OPEN ACCESS REVIEW ARTICLE

Strategies for the Use of Antithrombotic Drugs in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. A review Article

Mohammed Ali Khalifa [1], Abdullah. A. Alamoodi [1], Fares M.S Muthanna [1]

1 *Pharmacy Department, Faculty of Medicine Health Science, University of Science & Technology, Aden, Yemen*

ABSTRACT

Atrial fibrillation patients undergoing percutaneous coronary intervention pose a significant therapeutic challenge due to the need for effective anticoagulation and antiplatelet therapy. This review aims to provide a comprehensive framework for managing antithrombotic drugs in atrial fibrillation patients undergoing percutaneous coronary intervention, focusing on the integration of dual antiplatelet therapy and anticoagulants, and seeks to guide clinicians in selecting the optimal anticoagulation strategy based on patient-specific factors. The review examines the use of various anticoagulants, including unfractionated heparin, low molecular weight heparin, bivalirudin, warfarin, and direct oral anticoagulants, in combination with antiplatelet drugs. The review highlights their mechanisms of action, dosing regimens, and the increased bleeding risks associated with combination regimens. Key challenges, including bleeding risks, kidney function, and the choice of anticoagulant, are addressed, with a focus on optimizing the duration of dual antiplatelet therapy and considering triple therapy to reduce complications. Managing anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention involves balancing stroke prevention with bleeding risks. Tailored therapy based on individual risk factors and ongoing research is essential for optimizing outcomes and minimizing harm. Based on the evidence reviewed, we propose recommendations for managing anticoagulation, stressing the importance of balancing thromboembolic risk with bleeding complications.

Keywords: Atrial fibrillation, percutaneous coronary intervention, anticoagulation, dual antiplatelet therapy, bleeding risk, stroke prevention.

**** Corresponding author address:*** ***mmali198939@gmail.com***

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

INTRODUCTION

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, affecting an increasing number of patients globally, particularly those with underlying cardiovascular diseases. AF significantly elevates the risk of thromboembolic events, including stroke, due to left atrial blood stasis and subsequent clot formation [1]. When patients with AF undergo percutaneous coronary intervention (PCI) for coronary artery disease (CAD), the management of anticoagulation therapy becomes particularly challenging, requiring a careful balance between reducing thromboembolic risk and mitigating bleeding complications [2]. The integration of anticoagulants with antiplatelet regimens during and after PCI is essential for optimizing outcomes in these high-risk patients.[3]

The need for anticoagulation in AF patients undergoing PCI arises from the dual risk of stroke due to AF and stent thrombosis after PCI. Dual antiplatelet therapy (DAPT), typically comprising aspirin and a P2Y12 inhibitor, is standard after PCI to prevent stent thrombosis. However, adding anticoagulants to this regimen introduces complexities, increasing the risk of bleeding events, which are associated with adverse clinical outcomes, including increased mortality [4]. The development of direct oral anticoagulants (DOACs) has transformed the management of AF by offering predictable pharmacokinetics and a reduced need for monitoring compared to vitamin K antagonists (VKAs) [5, 6]. However, their role in the context of PCI remains under investigation.

AF is particularly prevalent in older adults and those with comorbid conditions such as hypertension, diabetes, and heart failure [1]. In PCI patients, AF is frequently associated with worse outcomes due to its propensity to increase thromboembolic events, complicate peri-procedural management, and extend hospital stays.[7]

The integration of DAPT with anticoagulation presents a significant clinical challenge. While DAPT is essential for preventing stent thrombosis, anticoagulation reduces the risk of cardioembolic stroke in AF patients. The triple therapy regimen of DAPT plus an anticoagulant, although effective in minimizing thrombotic risks, can increase the risk of major bleeding by up to four times compared to DAPT alone [8]. Recent guidelines recommend limiting triple therapy to the shortest duration possible, typically 1–3 months post-PCI, followed by dual therapy with an anticoagulant and a P2Y12 inhibitor .[2]

DOACs such as apixaban, rivaroxaban, and dabigatran are increasingly favored over VKAs for AF management due to their ease of use and favorable safety profile. However, their role in PCI remains nuanced. Studies such as RE-DUAL PCI and AUGUSTUS have explored the safety and efficacy of DOACs combined with antiplatelet therapy, demonstrating reduced bleeding risks compared to triple therapy with warfarin [9, 10]. The 2021 European Society of Cardiology (ESC) guidelines emphasize tailoring anticoagulation strategies based on the patient's individual thrombotic and bleeding risks, as assessed by tools like the CHA2DS2-VASc and HAS-BLED scores [1]. Similarly, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines recommend using DOACs in combination with a single antiplatelet agent in most AF patients undergoing PCI to reduce bleeding risks while maintaining efficacy.[11]

AF increases the risk of stroke and systemic embolism, particularly in the presence of other risk factors such as hypertension, diabetes, heart failure, and prior stroke or transient ischemic attack (TIA) [12]. Anticoagulation is essential in reducing the risk of thromboembolism in these patients. However, the use of anticoagulants in the setting of PCI—especially with the addition of antiplatelet therapy—requires a nuanced approach.[14 ,13]

PCI introduces the risk of procedural complications, including thrombosis of the stent and bleeding at the catheter insertion site [15]. Therefore, balancing anticoagulation therapy with antiplatelet drugs is crucial to avoid both thrombotic and hemorrhagic

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

events. This balance is further complicated by the type of coronary stents used (bare-metal vs. drug-eluting stents), the patient's comorbid conditions, and the timing of PCI.[12]

The primary anticoagulants used in AF patients undergoing PCI include Vitamin K antagonists (VKAs), DOACs, and UFH/LMWH. Each of these agents works through distinct mechanisms to prevent clot formation.[1]

Warfarin is the prototypical VKA, which inhibits the synthesis of clotting factors II, VII, IX, and X in the liver. VKAs require regular monitoring of the international normalized ratio (INR) and have numerous drug and food interactions. While effective in preventing thromboembolism in AF, VKAs are less commonly used in PCI due to the need for precise INR control and the increased bleeding risks during and after PCI.[16]

DOACs, including dabigatran (direct thrombin inhibitor), rivaroxaban, apixaban, and edoxaban (direct factor Xa inhibitors), have emerged as preferred alternatives to VKAs for stroke prevention in AF. These drugs have a fixed dosing schedule and do not require routine monitoring, making them more convenient. However, their role in PCI is still evolving, as they may not be as effective in preventing stent thrombosis as DAPT.[1]

Heparins, particularly LMWH, are commonly used peri-procedurally in PCI to reduce the risk of thrombosis. LMWH is preferred over unfractionated heparin due to its more predictable pharmacokinetics, requiring less frequent monitoring. Heparins are typically discontinued shortly after PCI and replaced with oral anticoagulants for long-term management of AF.[17]

The cornerstone of PCI management is the use of DAPT, which includes aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor). The addition of anticoagulation therapy in AF patients presents a challenge, as both anticoagulants and antiplatelet drugs increase the risk of bleeding .[9]

The most common strategy for AF patients undergoing PCI involves the use of both an oral anticoagulant (such as a DOAC) and DAPT. This approach aims to address both the thromboembolic risk associated with AF and the need for platelet inhibition to prevent stent thrombosis. However, the use of these drugs together significantly increases the bleeding risk. The optimal duration of DAPT in AF patients, along with the appropriate choice of anticoagulant, depends on the type of stent implanted, the patient's risk of bleeding, and their overall clinical profile.[12]

The duration of DAPT therapy is a key factor in reducing stent thrombosis risk without overly increasing bleeding. Recent guidelines recommend shorter durations of DAPT (1–3 months) for patients who receive drug-eluting stents (DES) and longer courses (6–12 months) for those with bare-metal stents (BMS). In patients with high bleeding risks, a shortened course of DAPT combined with oral anticoagulation may be preferred .[18]

"Triple therapy," which involves combining an anticoagulant (such as warfarin or a DOAC) with DAPT, is typically reserved for high-risk AF patients who require both stroke prevention and stent thrombosis prevention. However, this regimen significantly increases the risk of major bleeding complications. The decision to use triple therapy should be carefully considered, with close monitoring and a preference for shorter durations of triple therapy when possible.[1]

One of the major challenges when managing AF patients undergoing PCI is the increased risk of bleeding associated with anticoagulation and antiplatelet therapy. Major bleeding complications can lead to worse clinical outcomes, including prolonged hospitalization, need for transfusions, and increased mortality. Managing this risk involves individualizing treatment plans, using the least potent anticoagulant that provides effective stroke prevention, and carefully selecting the duration of antiplatelet therapy[9]

Many AF patients undergoing PCI have comorbid renal impairment, which can influence the pharmacokinetics and dosing of anticoagulant

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

medications [19]. DOACs, in particular, require dose adjustments based on renal function, and in cases of severe renal dysfunction, their use may be contraindicated. Close monitoring of renal function is necessary in this patient population.[20]

Although DOACs are favored over warfarin for stroke prevention in AF, their use in PCI is more complex [1]. For example, dabigatran, being a direct thrombin inhibitor, has been shown to be less effective than warfarin in preventing stent thrombosis when used with DAPT. Other DOACs, such as rivaroxaban or apixaban, are increasingly used in combination with antiplatelet agents, but the optimal combination and duration remain areas of ongoing research.[21]

This review explores the rationale for anticoagulation in AF patients undergoing PCI, the mechanisms of action of various anticoagulants, and strategies for balancing anticoagulation and antiplatelet therapy to optimize clinical outcomes. We aim to provide an updated overview of the evidence guiding anticoagulation management in this complex clinical scenario.

METHODOLOGY

Search Strategy

A comprehensive literature search was performed using PubMed, Embase, and Cochrane Library databases. Keywords included "atrial fibrillation," "percutaneous coronary intervention," "anticoagulants," "direct oral anticoagulants," "warfarin," "dual antiplatelet therapy," and "triple therapy." Articles published between 2010 and 2023 were prioritized to ensure up-to-date findings.

Inclusion Criteria

The inclusion criteria for this review were studies involving atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), including randomized controlled trials (RCTs), observational studies, and meta-analyses that assessed anticoagulation strategies. Eligible studies focused on outcomes related to thrombotic and bleeding events.

Exclusion Criteria

Studies will be excluded if they involve non-atrial fibrillation (AF) patients, case reports, or any non-peer-reviewed literature. Case report studies were excluded due to their limited generalizability and lack of rigorous methodologies, making them unsuitable for broader research conclusions.

MAIN FINDINGS

Anticoagulant Agents in AF Patients Undergoing PCI

Vitamin K Antagonists

VKAs, such as warfarin, have historically been the mainstay for stroke prevention in AF. Despite their efficacy, VKAs pose challenges in the PCI setting due to narrow therapeutic windows, need for frequent INR monitoring, and drug interactions. Studies indicate that while VKAs effectively prevent stroke, they confer higher bleeding risks in combination with DAPT.

Direct Oral Anticoagulants

DOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban, have largely replaced VKAs for stroke prevention in AF. They offer predictable pharmacokinetics, fewer interactions, and no routine monitoring. Clinical trials like Pioneer AF-PCI (rivaroxaban) and Re-Dual PCI (dabigatran) have demonstrated lower bleeding rates with DOAC-based regimens compared to warfarin.

Heparins

UFH and LMWH are commonly used during PCI to prevent periprocedural thrombosis. While effective intra-procedurally, these agents are not suitable for long-term anticoagulation in AF.

Anticoagulation and Antiplatelet Strategies

Dual Antiplatelet Therapy

DAPT with aspirin and a P2Y12 inhibitor (e.g., clopidogrel) is essential to prevent stent thrombosis

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

post-PCI. However, combining DAPT with systemic anticoagulation raises bleeding risks.

Triple Therapy

Triple therapy (DAPT + anticoagulant) is recommended for high-risk patients, but its prolonged use is discouraged due to bleeding concerns. Clinical guidelines suggest limiting triple therapy to 1–3 months, followed by anticoagulation plus a single antiplatelet agent.

Shortened DAPT

Evidence supports shorter DAPT durations (e.g., 1–3 months) for patients with high bleeding risk, particularly when drug-eluting stents (DES) are used. This strategy reduces bleeding while maintaining thrombotic protection.

Table 1: Summary of Antithrombotic Strategies in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
Adapted from American College of Cardiology (ACC)/American Heart Association (AHA) Guideline [16].

Therapeutic Category	Objective	Commonly Used Agents	Clinical Considerations
Anticoagulant agents	Prevention of thromboembolic events (e.g., systemic embolism, stroke)	Heparin, Bivalirudin, Direct Oral Anticoagulants such as Apixaban, Rivaroxaban, Dabigatran; Warfarin	Heparin or Bivalirudin is typically administered during PCI. DOACs are usually discontinued 24-48 hours pre-PCI; warfarin may be continued with strict INR monitoring.
Antiplatelet Therapy	Reduction of coronary artery thrombosis, including prevention of stent thrombosis	Aspirin, P2Y12* receptor inhibitors (Clopidogrel, Prasugrel, Ticagrelor)	Post-PCI, DAPT is recommended, typically involving aspirin and a P2Y12 inhibitor.
Bridging Therapy	Mitigation of thromboembolic risk during temporary cessation of oral anticoagulants	UFH, LMWH.	Bridging with UFH or LMWH may be necessary when DOACs or warfarin are interrupted before PCI to manage thromboembolic risk.

P2Y12*= platelet surface receptor which is inhibited by clopidogrel and similar drugs.

Anticoagulants like DOACs and Warfarin reduce the risk of thromboembolic events in AF patients but require adjustments around PCI due to bleeding risks. Short-acting agents like Bivalirudin or Heparin are preferred during the procedure, while oral anticoagulants are resumed post-PCI under close monitoring.

DAPT remains critical for preventing stent thrombosis. Drugs such as aspirin and P2Y12 inhibitors (e.g., Clopidogrel) are utilized, with therapy duration adjusted according to individual risk profiles to minimize bleeding complications

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

while ensuring thrombotic protection. Bridging with Heparin or LMWH is crucial when oral anticoagulants are temporarily discontinued. This strategy minimizes thromboembolism risk while providing flexibility during the peri-procedural period.

Clinical Considerations for Antithrombotic Management

Pre-PCI

Anticoagulation strategies during the pre-PCI phase often involve temporary discontinuation of oral anticoagulants like DOACs 24–48 hours before the procedure. Bridging therapy with UFH or LMWH is considered for high-risk patients to maintain anticoagulation during this period.

Intra-PCI

During PCI, UFH or bivalirudin is administered to prevent procedural thrombus formation. UFH is monitored using activated clotting time (ACT), while bivalirudin offers advantages in patients at high bleeding risk.

Post-PCI

In the short term, DAPT is prescribed to prevent stent thrombosis, with the duration tailored to patient bleeding risk and stent type. For long-term management, anticoagulation (DOAC or warfarin) is resumed to prevent stroke in AF patients.

Table 2: Anticoagulation Management in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Adapted from [22]

Phase	Anticoagulant Use	Medications	Key Considerations
Pre-PCI	Bridging or continuation of anticoagulation	LMWH, Warfarin, Direct Oral Anticoagulants	DOACs are usually stopped 24-48 hours prior to PCI. Bridging with heparin may be required if DOACs are interrupted.
Intra-PCI	Active anticoagulation during the procedure	UFH, Bivalirudin	Anticoagulation with heparin or bivalirudin; dosing adjusted based on the ACT.
Post-PCI (Short-Term)	Prevention of stent thrombosis and bleeding	DAPT: Aspirin + P2Y12 inhibitor	DAPT is maintained for 6-12 months post-PCI. Anticoagulants (DOAC or warfarin) continue for stroke prevention.
Post-PCI (Long-Term)	Long-term stroke prevention and coronary thrombus prevention	Warfarin, DOACs	Long-term use of warfarin or a DOAC is essential for ongoing stroke prevention in atrial fibrillation.

In AF patients, anticoagulants like DOACs are typically stopped 24–48 hours before PCI to reduce bleeding risks. High-risk patients may require bridging therapy using Heparin or LMWH to maintain anticoagulation during the gap.

Anticoagulants like UFH or Bivalirudin are administered to prevent thrombus formation during the procedure. Their doses are tailored based on intra-procedural metrics such as ACT, ensuring adequate clot prevention without excessive bleeding.

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

DAPT, consisting of aspirin and a P2Y12 inhibitor (e.g., Clopidogrel), is critical for preventing stent thrombosis. The duration of DAPT depends on stent type (e.g., drug-eluting or bare-metal) and bleeding risks. Anticoagulation for stroke prevention resumes alongside DAPT.

Once the risk of stent thrombosis is minimized, long-term anticoagulation focuses on stroke prevention in AF patients. DOACs or Warfarin are the mainstay therapies, with their choice guided by individual patient characteristics, including renal function and bleeding risks.

This comprehensive approach helps balance the dual risks of thromboembolism and bleeding, ensuring optimal outcomes for AF patients undergoing PCI.

UFH is the standard anticoagulant used during PCI due to its rapid onset and reversibility. Monitoring ACT ensures therapeutic levels during the procedure, but its short half-life makes it less useful outside PCI.

LMWH is commonly used for bridging therapy when DOACs or Warfarin are temporarily stopped before PCI. It has a predictable pharmacokinetic profile, requiring less monitoring than UFH, but dosing must be adjusted in patients with renal impairment.

The direct thrombin inhibitors are an alternative to UFH, particularly in patients at high bleeding risk. Its shorter duration of action and reduced bleeding rates make it ideal in specific PCI scenarios.

DOACs are increasingly favored for long-term stroke prevention in AF due to their ease of use and lack of routine monitoring. However, they must be discontinued 24–48 hours before PCI to minimize bleeding risks, and renal function monitoring is critical.

Despite being effective for stroke prevention, Warfarin requires careful INR monitoring due to its narrow therapeutic range. Its reversibility remains a significant advantage in cases of bleeding or urgent procedures.

This categorization and consideration framework provide clarity on anticoagulant use during various stages of PCI, ensuring patient-specific management of thrombotic and bleeding risks.

Table 3: Dosing of Anticoagulants and Antiplatelets for AF Patients Undergoing PCI
Adapted from [22]

Anticoagulant	Indication	Dosing Regimen	Key Notes
Unfractionated Heparin	Active anticoagulation during PCI	Loading dose: 60–70 IU/kg IV bolus (usually 5000–7000 IU)	Adjust based on ACT, typically target ACT 250–300 seconds.
		Maintenance dose: Infusion of 12–15 IU/kg/h IV, adjusted to maintain ACT or anti-Xa level	Reversed with protamine sulfate if bleeding occurs.
Bivalirudin	Active anticoagulation during PCI	Loading dose: 0.75 mg/kg IV bolus	Direct thrombin inhibitor, preferred in high-bleeding risk situations.
		Maintenance dose: 1.75 mg/kg/hr IV infusion	No need for routine monitoring of ACT; may

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

			be adjusted based on clinical response.
Low Molecular Weight Heparin	Bridging therapy or PCI anticoagulation	Enoxaparin: 1 mg/kg subcutaneously every 12 hours (for bridging)	Adjust for renal function (use lower doses in renal insufficiency). Does not require routine ACT.
Aspirin	Loading dose: 160–325 mg orally (preferably chewable) at the time of PCI	Long-term: 81–100 mg daily orally	Aspirin should be continued long-term after PCI to prevent stent thrombosis.
	Maintenance dose: 81 mg daily orally (commonly used dose)		Typically continued for at least 12 months after stent placement (depending on clinical risk).
Clopidogrel	Loading dose: 600 mg orally (given 24 hours before PCI or at the time of PCI)	Maintenance dose: 75 mg daily orally	If a bare-metal stent (BMS) is used, the minimum recommended duration is 1 month. If a drug-eluting stent (DES) is used, the duration is 6 months to 1 year.
Prasugrel	Loading dose: 60 mg orally (given 24 hours before PCI or at the time of PCI)	Maintenance dose: 10 mg daily orally	Prasugrel is generally preferred for PCI in patients without a history of stroke or TIA, especially for those undergoing DES implantations. Minimum duration: 6 months.

UFH remains the primary anticoagulant during PCI due to its reversibility and ease of monitoring via ACT.

Bivalirudin, a direct thrombin inhibitor, is an alternative in patients with a high bleeding risk due to its reduced hemorrhagic complications and predictable pharmacokinetics.

LMWH is primarily used when oral anticoagulants (Warfarin or DOACs) are stopped before PCI. Its predictable effects reduce the need for frequent monitoring. However, it is generally avoided during PCI itself.

Warfarin is a traditional option, with the advantage of reversibility through Vitamin K or fresh frozen plasma, but requires regular INR monitoring.

DOACs are increasingly favored for their convenience and lack of routine monitoring, although careful consideration is needed for dosing in renal impairment and timing before PCI to avoid excess bleeding.

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

Reversal is achieved with protamine sulfate, which neutralizes heparin. The dosing is approximately 1 mg of protamine for every 100 IU of heparin. UFH is reversible, but it requires monitoring during and after its use. This agent is commonly used during PCI procedures but must be reversed quickly if bleeding occurs [23].

Bivalirudin has no specific reversal agent. Its effects can be reversed by simply discontinuing the infusion. Given its short half-life, it clears from the system rapidly, but its lack of a dedicated reversal agent makes it less flexible in certain high-risk bleeding situations [24].

Protamine sulfate can partially reverse LMWH, but it is less effective than in UFH, as it only reverses about 50% of the anticoagulant effect. This makes LMWH less ideal for use during PCI, though it is commonly used in bridging therapy [25].

The reversal of warfarin involves the administration of vitamin K, either orally or intravenously, especially in urgent cases. Regular monitoring of INR is essential during warfarin therapy, and vitamin K can be used to correct elevated INR levels when necessary [26].

For dabigatran, idarucizumab is the specific reversal agent, while andexanet alfa is used for factor Xa inhibitors like rivaroxaban and apixaban. These reversal agents are used in cases of major bleeding or urgent procedures, but they are specific to the type of DOAC [27]. Each anticoagulant's reversal strategy is tailored to its pharmacological profile, with agents like protamine sulfate being effective for heparin and vitamin K for warfarin, while newer agents like idarucizumab and andexanet offer specific reversal for DOACs. These strategies help manage the risks of bleeding while ensuring effective anticoagulation during and after PCI.

Table 4: Duration of Dual Antiplatelet Therapy (DAPT) in AF with PCI
Adapted from [28 and 32]

Type of Stent	Standard DAPT Duration	Considerations for Duration
Bare-metal stent (BMS)	Minimum: 1 month	Shorter DAPT duration (1 month) in patients with low bleeding risk and low thrombosis risk.
Drug-eluting stent (DES)	6–12 months	Longer DAPT duration to reduce risk of stent thrombosis. Duration can be adjusted based on bleeding risk.
High bleeding risk	Shortened DAPT duration	In patients with high bleeding risk, DAPT duration may be shortened (e.g., 3–6 months).
Low bleeding risk	Full DAPT duration (6–12 months)	For patients at low bleeding risk, standard DAPT duration (6–12 months) is recommended.

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

Table 5: Summarizing the mechanisms of action for antithrombotic drugs commonly used in atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI):

Drug Class	Drug Examples	Mechanism of Action	Target
Antiplatelet Agents	Aspirin	Inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production, which prevents platelet aggregation.	Platelets
	P2Y12 Inhibitors: Clopidogrel, Prasugrel, Ticagrelor	Block the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation.	Platelets
Vitamin K Antagonists	Warfarin	Inhibits vitamin K epoxide reductase, reducing synthesis of clotting factors II, VII, IX, and X.	Liver (clotting factor synthesis)
Direct Oral Anticoagulants (DOACs)	Dabigatran	Directly inhibits thrombin (factor IIa), preventing fibrin formation and thrombus growth.	Thrombin (Factor IIa)
	Rivaroxaban, Apixaban, Edoxaban	Directly inhibit factor Xa, reducing thrombin generation and clot formation.	Factor Xa
Heparins	Unfractionated Heparin (UFH)	Enhances antithrombin activity, inhibiting factors IIa (thrombin) and Xa.	Heparins
	Low Molecular Weight Heparins (LMWH): Enoxaparin, Dalteparin	Primarily inhibits factor Xa via antithrombin activation.	
Glycoprotein IIb/IIIa Inhibitors	Abciximab, Eptifibatide, Tirofiban	Block the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen binding and platelet aggregation.	Glycoprotein IIb/IIIa Inhibitors

Table 5 provides an overview of the mechanisms of action for antithrombotic drugs commonly used in patients with atrial fibrillation (AF) who are undergoing percutaneous coronary intervention (PCI). It categorizes these drugs into their respective classes, lists specific examples, explains their mechanisms of action [33], and identifies their primary molecular or cellular targets. It also highlights the diversity of pharmacological approaches in managing thrombotic risk during PCI in AF patients. Each drug class targets a specific component of the coagulation or platelet activation cascade:

https://doi.org/10.20428/yjms.v19i1.2626
https://journals.ust.edu/index.php/yjms

Antiplatelet Agents (e.g., Aspirin, P2Y12 inhibitors) work primarily by inhibiting platelet aggregation, crucial in arterial thrombus formation.

Vitamin K Antagonists (e.g., Warfarin) and Direct Oral Anticoagulants (DOACs) (e.g., Dabigatran, Rivaroxaban) inhibit key coagulation factors, reducing clot formation.

Heparins enhance the activity of natural anticoagulants (antithrombin), while Glycoprotein IIb/IIIa Inhibitors prevent platelet-fibrinogen interaction, further suppressing platelet aggregation.

DISCUSSION

Anticoagulation management in AF patients undergoing PCI requires individualized strategies to optimize outcomes. Clinical trials have highlighted DOACs as safer alternatives to warfarin in reducing bleeding without compromising efficacy. Shortened DAPT durations and single therapy regimens further mitigate bleeding risks. Challenges remain in addressing renal impairment, which affects DOAC dosing, and in selecting anticoagulants with minimal drug-drug interactions.

Guidelines emphasize balancing thrombotic and bleeding risks by considering stent type, patient comorbidities, and procedural characteristics. Personalized therapy, guided by validated risk scores like CHA_2DS_2-VASc and HAS-BLED, is crucial for decision-making.

AF is the most common arrhythmia, and when combined with CAD, it often necessitates PCI to address ischemic heart disease. This dual pathology complicates anticoagulation management, as patients are at increased risk for both thromboembolic events and bleeding. The use of anticoagulants in this patient population is essential but requires careful consideration of various factors, including the timing of anticoagulation, the choice of agents, and the risk of bleeding complications.

Table 1 illustrates the various anticoagulant therapies used in AF patients undergoing PCI, including heparin, bivalirudin, d DOACs, and warfarin. Heparin, particularly UFH, is commonly used during PCI for active anticoagulation, as it can be quickly reversed with protamine sulfate if bleeding occurs [27]. In contrast, bivalirudin, another option during PCI, is a direct thrombin inhibitor that does not require routine monitoring of ACT and is preferred in high-bleeding-risk situations. However, bivalirudin lacks a specific reversal agent, which can be a limitation in certain emergency situations [29].

In comparison, DOACs like apixaban, rivaroxaban, and dabigatran are favored for long-term stroke prevention in AF patients but are generally discontinued 24–48 hours before PCI due to their long half-life and bleeding risks. Interestingly, studies have shown that while DOACs are preferred over warfarin for stroke prevention in AF, they are not as effective as DAPT in preventing stent thrombosis post-PCI [30]. This is significant because AF patients undergoing PCI require both anticoagulation for stroke prevention and antiplatelet therapy to prevent stent thrombosis. The combination therapy increases the risk of bleeding, requiring careful balancing and close monitoring [31].

The choice of anticoagulant and timing of therapy is critical. According to the guidelines described in [26], LMWH is often used as a bridging agent when patients are off long-term oral anticoagulation like warfarin. LMWH has a more predictable pharmacokinetic profile compared to UFH, and it requires less frequent monitoring. However, its use in PCI is less common as UFH or bivalirudin are preferred due to their ability to be more precisely adjusted during the procedure [27]. The use of LMWH for bridging is particularly common in patients transitioning from warfarin to a procedural anticoagulation regimen. Studies have demonstrated that bridging with LMWH is often necessary to minimize thromboembolic risks when DOACs or warfarin are temporarily stopped before PCI [29].

Warfarin remains a standard treatment for long-term anticoagulation in AF patients, especially when transitioning off DOACs or in cases with renal impairment where DOACs are contraindicated. Warfarin's primary disadvantage lies in its need for

regular INR monitoring, which can complicate its use, especially in patients undergoing PCI who require precise anticoagulation control [26]. Despite this, warfarin can be continued during PCI with close INR monitoring, making it an option when more modern agents are not appropriate.

Reversal agents play a pivotal role in managing bleeding risks associated with anticoagulant therapy. As shown in Table 2, the reversal of heparin and LMWH involves the use of protamine sulfate. However, the reversal of LMWH is only partial, as it does not completely neutralize the anticoagulant effect [25]. Bivalirudin poses a unique challenge in that it does not have a specific reversal agent, which can complicate its use in patients at high risk of bleeding. Conversely, the newer DOACs have specific reversal agents like idarucizumab for dabigatran and andexanet alfa for the factor Xa inhibitors (rivaroxaban and apixaban). The availability of these reversal agents provides a more definitive approach to managing bleeding complications in DOAC-treated patients [29].

Studies examining the efficacy of reversal agents suggest that while they offer timely intervention for patients experiencing major bleeding, they are not without limitations. For instance, the cost and availability of specific reversal agents such as andexanet alfa may affect their use in some healthcare settings, highlighting a key area for improvement in clinical practice [30].

While current therapies and reversal strategies offer effective solutions, several challenges remain. The risk of bleeding continues to be a significant concern when combining anticoagulation with antiplatelet therapy, particularly in AF patients undergoing PCI [25]. Despite advancements in anticoagulation agents like DOACs, there is still no perfect solution that offers both efficacy and safety for all patients. While shorter DAPT durations (1–3 months) are recommended for patients with drug-eluting stents, further studies are needed to determine the ideal duration in high-risk bleeding patients [29].

Finally, the complexity of managing renal function in AF patients undergoing PCI adds another layer of challenge, as both DOACs and warfarin require adjustments based on renal clearance [27]. Monitoring and adjusting dosing in these patients are crucial to avoid complications such as bleeding or thromboembolic events.

CONCLUSION

Managing anticoagulation in AF patients undergoing PCI is a complex task that requires balancing the risks of thromboembolic events and bleeding complications. The combination of anticoagulant and antiplatelet therapy effectively reduces the risk of stroke and stent thrombosis; however, the significant increase in bleeding risk remains a critical challenge. Optimizing patient outcomes requires a tailored approach that carefully considers individual risk factors, including renal function, bleeding propensity, and the type of coronary stent deployed. Ongoing research and evolving clinical guidelines continue to refine anticoagulation strategies, aiming for a personalized approach that maximizes benefits while minimizing harm. Additionally, the optimal duration of DAPT, particularly in AF patients receiving drug-eluting stents, remains an area of ongoing research.

REFERENCES

[1] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612

[2] Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. https://doi.org/10.1093/eurheartj/ehaa575

[3] Sammut MA, Conway D, Iqbal J, Krishnamurthy A, Morgan KP, Morris PD, et al. Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation. Expert Rev Cardiovasc Ther. 2024;22(7):339–345. https://doi.org/10.1080/14779072.2024.2374366

[4] Lip GY, Banach M, Boriani G, Chiang CE, Freedman B, Lane DA, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2019;155(6):1221–1223. https://doi.org/10.1016/j.chest.2018.11.035

[5] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561

[6] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. https://doi.org/10.1056/NEJMoa1009638

[7] Hamaguchi T, Iwanaga Y, Nakai M, Morita Y, Inoko M. Clinical significance of atrial fibrillation status in patients with percutaneous coronary intervention. CJC Open. 2021;3(11):1357–1364. https://doi.org/10.1016/j.cjco.2021.06.018

[8] Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with AF undergoing PCI. N Engl J Med. 2016;375(25):2423–2434. https://doi.org/10.1056/NEJMoa1611594

[9] Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–1524. https://doi.org/10.1056/NEJMoa1708454

[10] Lopes RD, Hong H, Granger CB, Jolly SS, Kesaniemi YA, Verheugt FW, et al. Safety and efficacy of apixaban versus warfarin in patients with atrial fibrillation and a history of coronary or peripheral artery disease. Am Heart J. 2019;217:96–104. https://doi.org/10.1016/j.ahj.2019.07.003

[11] Choi JM, Yang SY, Lee SR, Cho MS, Lee KY, Ahn HJ, et al. Increasing very low-dose edoxaban: Effectiveness and safety data of Korean AF patients. Korean Circ J. 2025;55. https://doi.org/10.4070/kcj.2024.0222

[12] Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385(18):1643–1655. https://doi.org/10.1056/NEJMoa2108749

[13] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210

[14] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;64(21):e1–e76. https://doi.org/10.1016/j.jacc.2014.03.022

[15] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394

[16] January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update on atrial fibrillation: An update of the 2014 guideline. J Am Coll Cardiol. 2019;74(1):104–132. https://doi.org/10.1016/j.jacc.2019.01.011

[17] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline on duration of dual antiplatelet therapy. J Am Coll Cardiol. 2016;68(10):1082–1115. https://doi.org/10.1016/j.jacc.2016.03.513

[18] Cutlip DE, Windecker S, Mehran R, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394

[19] Pratley R, Barr P, Butcher I. Anticoagulation in atrial fibrillation with renal impairment: Evidence review. Eur J Intern Med. 2020;72:24–32. https://doi.org/10.1016/j.ejim.2020.06.012

[20] Gomez-Outes A, Lagunar-Ruiz JP, de la Morena G. Pharmacokinetics of direct oral anticoagulants in renal impairment. J Thromb Haemost. 2018;16(12):2367–2379. https://doi.org/10.1111/jth.14300

[21] Nielsen LR, Sørensen R, Berg SK. DOACs in percutaneous coronary intervention: Evidence review. Cardiovasc Drugs Ther. 2021;35(5):909–920. https://doi.org/10.1007/s10557-021-07157-6

[22] Angiolillo DJ, et al. Antithrombotic therapy in atrial fibrillation undergoing PCI: Review. J Am Coll Cardiol. 2021;77(5):629–47.

[23] Choi JH, Chun KJ, Jung SM, et al. Safety of heparin reversal after PCI. BMC Cardiovasc Disord. 2022;22(1):207. https://doi.org/10.1186/s12872-022-02650-5

[24] Joppa SA, Salciccioli J, Adamski J, et al. Review of DOACs and reversal agents. J Clin Med. 2018;7(2):29. https://doi.org/10.3390/jcm7020029

[25] Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Protamine effects on heparins. Thromb Haemost. 1995;73(3):439–43.

[26] Cangemi R, Tomasetti M. Anticoagulation therapy in PCI: Review. Cardiol Clin. 2021;39(4):561–577. https://doi.org/10.1016/j.ccl.2021.07.005

[27] Harmon DA, Wittkowsky AK. Antithrombotic therapy in PCI: Strategies. J Thromb Thrombolysis. 2022;54(2):321–332. https://doi.org/10.1007/s11239-022-02544-0

[28] Valgimigli M, Costa F. Dual antiplatelet therapy strategies. J Am Coll Cardiol. 2021;78(21):2060–72.

[29] Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants. Thromb Haemost. 2015;113(5):931–42.

[30] Xian Y, Xu H, O'Brien EC, et al. Effectiveness of DOACs vs warfarin in stroke. JAMA Neurol. 2019;76(10):1192–1202. https://doi.org/10.1001/jamaneurol.2019.2099

[31] Chan NC, Weitz JI. New directions in antithrombotic therapy. Circ Res. 2019;124(3):426–36.

[32] Valgimigli M, Costa F. Review of antithrombotic therapy strategies. Circ. 2019;139(9):1063–1076. https://doi.org/10.1161/CIRCULATIONAHA.118.037826

[33] Zhang L, Li Z, Ye X, Chen Z, Chen ZS. Mechanisms of thrombosis and research progress on targeted antithrombotic drugs. Drug Discovery Today. 2021 Oct 1;26(10):2282-302.